Research, news and information on the effectiveness of oral pre-exposure prophylaxis (PrEP) and its impact on HIV epidemics, as well as clinical issues for PrEP users.

PrEP science: latest news

PrEP science news from aidsmap

More news

PrEP science news selected from other sources

  • Can PrEP on Demand for HIV Prevention Work in the U.S.? Experts Answer Your Questions

    The efficacy of on-demand PrEP is uncontroversial, but work is still needed to inform clinicians, PrEP programs, and other HIV programs serving communities of color in the U.S. This was the central theme of a panel discussion about on-demand PrEP at the recent December 3-4 Biomedical HIV Prevention Summit, held December 3 and 4 in Los Angeles.

    17 December 2018 | The Body Pro
  • No new infections during research on preventive HIV pill in Belgium

    According to the latest figures from Sciensano, 890 new diagnoses were made in Belgium last year, mainly in gay men and people from sub-Saharan Africa. This is a decrease of 27% compared to the peak of 2012.

    27 November 2018 | Institute of Tropical Medicine
  • HIV Seroconversion Despite PrEP Therapy

    The tragedy of continued HIV transmission in the era of pre-exposure prophylaxis (PrEP) is explored in detail in a viewpoint article published in Clinical Infectious Diseases.1 The study evaluated a cohort of 14 young black men who have sex with men (MSM) in Atlanta, Georgia, who experienced HIV seroconversion despite administration of PrEP as part of the EleMENt Study.

    22 November 2018 | Infectious Disease Advisor
  • Trying to prevent and diagnose HIV at the same time – a Catch-22?

    The doctors were puzzled by the fact that it wasn’t quite HIV. If it became HIV they could treat it. If it didn’t become HIV and went away they could discharge him. But this just being short of HIV all the time confused them.

    11 November 2018 | Daily Maverick
  • How to evaluate PrEP and vaccines: urgency for next generation compounds

    Several presentations at R4P 2018 looked at the new challenges of evaluating efficacy of new PrEP and vaccine candidates.

    05 November 2018 | HIV i-Base
  • PrEP Is Safe for Pregnant Women Who Want the HIV Prevention Drug, a New Study Finds

    Pre-exposure prophylaxis, or PrEP, is safe for pregnant women to use, according to new research presented at the HIV Research for Prevention (HIVR4P2018) conference in Madrid, Spain.

    05 November 2018 | The Body Pro
  • How substance use affects adherence to PrEP among gay and bisexual men

    On average, club drug users were no more likely to miss a dose of PrEP than non-club drug users. However, club drug use (at the event level) increased the odds of missing a dose on the same day by 55 percent and the next day (e.g., a "carryover effect") by 60 percent. "This suggests that although club drug users appeared to have similar aggregate levels of adherence, their missed doses were specifically timed around instances of club drug use.

    24 October 2018 | Medical Xpress
  • First U.S. Failure of Truvada as PrEP Is Reported at IDWeek

    A poster presentation at IDWeek, a yearly conference held by the Infectious Diseases Society of America, revealed that a 21-year-old Latinx man has acquired HIV despite consistently high adherence to pre-exposure prophylaxis (PrEP). This new report is unique for several reasons, primarily because this is the first known HIV seroconversion with verified adherence to PrEP in the U.S.

    07 October 2018 | The Body Pro
  • Making Clinical Trials of PrEP More Inclusive of Women, No Matter Their Pregnancy Status

    Three new trials of HIV prevention drugs seek to answer directly a question that researchers inside and outside the field of HIV have explicitly avoided for years: How do drugs work -- and are they safe -- in pregnant and breastfeeding women?

    01 October 2018 | The Body Pro
  • Swapping daily pills for monthly shots could transform HIV treatment and prevention

    New results are raising hopes for easing one challenge of living with HIV: the need to take daily pills for life, both to ward off AIDS and to lower the risk of transmitting the virus to others. Missing doses can also foster the emergence of HIV strains with drug resistance, a danger both to the person receiving treatment and, if those strains spread, to entire populations. Now, a large-scale study has shown over 48 weeks that monthly injections of two long-acting anti-HIV drugs work just as well as taking daily pills.

    23 August 2018 | Science
More news
Tell us why you visited aidsmap today
minimise

Could you help us by answering three questions on why you’ve visited aidsmap today?

You can close this questionnaire and come back to it later. Just click on the pink circle.

What prompted you to visit aidsmap today?

What exactly are you looking for? What specific questions do you need answered?

Have you found what you were looking for?

close

Thank you for your feedback

Thank you very much for taking time to fill in this questionnaire. NAM really values your feedback. It helps make the information we provide better.

If you have any other comments on the content of this website, we would be interested to hear from you. Please email info@nam.org.uk.

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.